Created at	Source	Raw Value	Validated value
June 23, 2022, 8:30 p.m.	usa	The primary endpoint is the -fold increase in antibody titer (using the Roche Elecsys® anti-SARS-CoV-2 S assay) from before receiving the study dose of vaccine to 30 days after the study dose of vaccine.	The primary endpoint is the -fold increase in antibody titer (using the Roche Elecsys® anti-SARS-CoV-2 S assay) from before receiving the study dose of vaccine to 30 days after the study dose of vaccine.
Oct. 16, 2021, 3 p.m.	usa	Proportion of Participants Who Achieve an Antibody Response >50 U/mL	Proportion of Participants Who Achieve an Antibody Response >50 U/mL